Actinogen Suspended As It Analyses XanaMIA Alzheimer’s Trial Data
Actinogen Medical has requested a voluntary suspension while it completes further analysis of additional data received for its XanaMIA phase 2b/3 Alzheimer’s trial, ahead of releasing topline results. The suspension is requested to remain in place until the results announcement or the start of trading on Thursday.

Comments